Colon cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Colon cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Dostarlimab with CAPEOX and CAPEOX Alone for Patients with Untreated Stage III Colon Cancer https://clinicaltrials.eu/trial/study-comparing-dostarlimab-with-capeox-and-capeox-alone-for-patients-with-untreated-stage-iii-colon-cancer/ Wed, 29 Apr 2026 14:58:11 +0000 https://clinicaltrials.eu/trial/study-comparing-dostarlimab-with-capeox-and-capeox-alone-for-patients-with-untreated-stage-iii-colon-cancer/ This clinical trial is focused on studying a type of colon cancer known as Stage III MMRp/MSS colon cancer. The study is investigating the effectiveness and safety of a treatment that combines two medications: dostarlimab and CAPEOX. Dostarlimab is a medication that helps the immune system fight cancer, and it is also known by the code names WBP-285 and TSR-042. CAPEOX is a combination of two chemotherapy drugs, capecitabine and oxaliplatin, which are used to kill cancer cells. The purpose of the study is to compare the effects of using dostarlimab with CAPEOX against using CAPEOX alone in patients who have not received any previous treatment for their cancer.

Participants in the study will be randomly assigned to receive either the combination of dostarlimab and CAPEOX or CAPEOX alone. The study will last for a period of up to 12 months, during which participants will receive their assigned treatment. The treatments will be administered either orally, in the form of tablets, or intravenously, which means through a vein. Throughout the study, participants will be closely monitored to assess how well the treatment is working and to check for any side effects. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment.

The study aims to provide valuable information on whether adding dostarlimab to the standard CAPEOX treatment can improve outcomes for patients with Stage III MMRp/MSS colon cancer. By participating in this study, researchers hope to find more effective ways to treat this type of cancer and improve the quality of life for those affected. The results of this study could lead to new treatment options for patients in the future.

]]> Study on Botensilimab Alone and with Balstilimab or Drug Combination for Patients with Refractory Metastatic Colorectal Cancer https://clinicaltrials.eu/trial/study-on-botensilimab-alone-and-with-balstilimab-or-drug-combination-for-patients-with-refractory-metastatic-colorectal-cancer/ Wed, 29 Apr 2026 14:24:44 +0000 https://clinicaltrials.eu/trial/study-on-botensilimab-alone-and-with-balstilimab-or-drug-combination-for-patients-with-refractory-metastatic-colorectal-cancer/ This clinical trial is focused on studying treatments for Refractory Metastatic Colorectal Cancer, a type of cancer that has spread to other parts of the body and does not respond to standard treatments. The study will explore the effectiveness of a new treatment called Botensilimab (also known as AGEN1181) both on its own and in combination with another treatment called Balstilimab (also known as AGEN2034). Additionally, the study will compare these treatments to the standard care options, which include Regorafenib and a combination of Trifluridine and Tipiracil.

The purpose of the study is to evaluate how well these treatments work in patients with this type of cancer. Participants in the study will be randomly assigned to receive either Botensilimab alone, Botensilimab with Balstilimab, or one of the standard care treatments. The study will monitor the participants over a period of time to see how their cancer responds to the treatment they receive. This will help researchers understand which treatment options might be most effective for patients with this challenging form of cancer.

Throughout the study, participants will receive regular check-ups and assessments to track their health and the progress of their cancer. The study aims to provide valuable information that could lead to better treatment options for people with Refractory Metastatic Colorectal Cancer in the future. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]>